EU-IPFF committed to promoting research in Pulmonary Fibrosis

Determination of Functional Exercise Capacity, Respiratory Muscle Endurance in Idiopathic Pulmonary Fibrosis

Study Purpose

There are not enough studies in the literature comparing functional capacity, respiratory functions and muscle strength of IPF patients with healthy individuals. This study aims to compare functional capacity, respiratory functions and muscle strength of IPF patients with healthy individuals.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	Yes
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Being over 18 years old.

- having a clinical, radiological and/or pathological diagnosis of IPF.

- volunteering to participate in the study.

- not having had a respiratory tract infection in the last month.

- not having an accompanying airway disease such as COPD.

- being in the stable phase of the disease.

Exclusion Criteria:

- Patients who have had an IPF attack within the last three months and/or are in the acute exacerbation of the disease; who use a walking aid; who have unstable angina or class III-IV heart failure according to the New York Heart Association congestive heart failure classification; who have orthopedic, neuromuscular, neurological and cardiac diseases that may affect walking and balance; who have serious comorbid conditions such as cancer or neoplasm; who have a history of sarcoidosis, tuberculosis, emphysema and/or lung surgery; who have communication problems, mental and cognitive problems, and who cannot adapt to the applied assessment methods will be excluded from the study.

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06668051
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Hacettepe University
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Not yet recruiting
Countries
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Idiopathic Pulmonary Fibrosis, Healthy

Arms & Interventions

Arms

: IPF

Inclusion Criteria: Being over 18 years old -having a clinical, radiological and/or pathological diagnosis of IPF -volunteering to participate in the study -not having had a respiratory tract infection in the last month -not having an accompanying airway disease such as COPD -being in the stable phase of the disease Exclusion Criteria: Patients who have had an IPF attack within the last three months and/or are in the acute exacerbation of the disease; who use a walking aid; who have unstable angina or class III-IV heart failure according to the New York Heart Association congestive heart failure classification; who have orthopedic, neuromuscular, neurological and cardiac diseases that may affect walking and balance; who have serious comorbid conditions such as cancer or neoplasm; who have a history of sarcoidosis, tuberculosis, emphysema and/or lung surgery; who have communication problems, mental and cognitive problems, and who cannot adapt to the applied assessment methods will be

: HEALTHY GROUP

Being over 18 years old -having a clinical, radiological and/or pathological volunteering to participate in the study -not having had a respiratory tract infection in the last month -not having an accompanying airway disease such as COPD